Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03572426 · ClinicalTrials.gov registry record
Ion Channel Genetic Biomarkers: Diagnostic Capabilities in the Assessment of Bipolar Disorder
A clinical trial, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- 164
- Enrollment target
NCT03572426: Completed study, sponsored by University of Colorado, Denver.
NCT03572426 is a clinical trial that has completed, run by University of Colorado, Denver. The registered enrollment target is 164 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03572426 has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- 164 participants
- Enrollment target
Study Summary
Genotype 164 adults to evaluate six selected single nucleotide polymorphisms (SNPs) (rs1006737, rs10994336, rs10994133, rs2238071, rs1051375, rs1024582) for use as a genetic biomarker to differentiate between bipolar depression and unipolar depression.
Primary Outcome
Logistic regression will be used to examine a genetic risk score using a risk allele count as the independent variable, with a diagnosis of BD versus MDD versus those with no mood diagnosis as the dependent variable.
Interventions
- OTHER genotyping all subjects
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 164 participants |
| Start Date | 2018-06-13 |
| Est. Completion | 2019-04-04 |
What the finished NCT03572426 record still lists
NCT03572426 is an observational study that tracks outcomes without assigning an intervention. The registered 164 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which genotyping all subjects is the first listed.
NCT03572426 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03572426 about?
NCT03572426 is a clinical study titled "Ion Channel Genetic Biomarkers: Diagnostic Capabilities in the Assessment of Bipolar Disorder". Genotype 164 adults to evaluate six selected single nucleotide polymorphisms (SNPs) (rs1006737, rs10994336, rs10994133, rs2238071, rs1051375, rs1024582) for use as a genetic biomarker to differentiate between bipolar depression and unipolar depression.
What is the current status of trial NCT03572426?
This trial is currently completed. The enrollment target is 164 participants. The study started on 2018-06-13. Estimated completion is 2019-04-04.
What interventions are being tested in trial NCT03572426?
The interventions under investigation include: genotyping all subjects (OTHER).
Who is sponsoring clinical trial NCT03572426?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04891289 · 164 participants · Phase 2
Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery
- NCT04893226 · 164 participants · NA
Time-Restricted Feeding Intervention in Metabolically-Unhealthy Postmenopausal Women
- NCT05270213 · 164 participants · Phase 1
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
- NCT05543681 · 164 participants · Phase 2
Clinical Trial on Agitation in Alzheimer's Dementia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI